ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. - Wikidata - wikimedia - TriplyDB

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

http://www.wikidata.org/entity/Q37200831

about

Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context.Mesenchymal stem cell-conditioned medium promotes MDA-MB-231 cell migration and inhibits A549 cell migration by regulating insulin receptor and human epidermal growth factor receptor 3 phosphorylation.HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.Molecular mechanisms regulating the hormone sensitivity of breast cancer.An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness.The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis.ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation.Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer.Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors.Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.Predicting high-risk endometrioid carcinomas using proteins.Activating HER3 mutations in breast cancer.

P2860

Q29248893-ECA91B0F-8191-412B-8B81-13BE21B0AA66 Q30238959-592CFBC2-9928-48E4-9392-E38533E3F4F5 Q33597555-4EC6F9B8-BCEE-4580-AD83-5502FC8E0711 Q33823200-C22CE496-F3B5-42EB-8163-704692EAF12C Q33859205-A023FA3E-929F-425A-A8B6-7565823EE997 Q33917876-E07BC4CB-2055-4BF8-8935-648BE0164921 Q34813272-FE619536-3615-42C2-9FFB-7448CDE53C69 Q35610581-D115CA6B-5D6C-4FA6-BBD3-6D9E08EB4698 Q35713360-2A41C6F7-8919-4922-AFA6-0BEAABE3F34D Q35927942-1EC4CE81-D5B2-416B-9F4F-67BABCE2A176 Q36359705-719F3A29-0AF6-4C14-B90F-AF2C7E004367 Q36437261-C44089B5-3818-4B25-BA82-F9D2D47F90BD Q38385463-1EB5F62C-1F85-4DD1-A44B-61B073F8A58F Q38710164-303131BB-71C6-49BD-8885-779BCF28CB03 Q38876630-7CBCB915-19E6-49D8-B9EA-A44393C27F25 Q38890318-3796B8AB-7EF8-43FD-B2A6-6585DC0B2A91 Q39028181-A2028B2C-D1EF-4133-97FC-A7BF56CF3AD5 Q40745811-408EFBA2-4BDF-4C4A-ACEB-F55B4FED58CC Q41135979-BADD30E2-01E7-47B4-829A-A135307EFE1B Q41467086-716A4189-2267-4B6F-B044-89CC35B76D06 Q47203450-874A2295-F800-470E-95D5-32AE25945D7F Q48209624-C1AA6502-07AD-489B-974B-7F142046DD85 Q49988930-5BD89410-B9C6-4353-AB25-CF75189EC276 Q51472977-6BB0D689-BE6E-4730-A843-232A44BB84B6 Q52390750-EA193F0D-2E08-4606-A362-0103713EEBC8 Q55368257-D233CB63-1A20-4EC5-A318-84CB257175A9 Q55379622-0C55896E-0D7A-4D53-B713-F7D265CB1B0D

P2860

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

http://www.wikidata.org/entity/Q37200831

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

@en

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

@nl

type

label

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

@en

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

@nl

prefLabel

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

@en

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

@nl

P1433

Q37200831-2E505929-7879-47BD-90C3-7D385688371F

P1476

Q37200831-85956F89-6913-426D-8836-A62E3561E5E8

P2093

Q37200831-0BB9366E-46DE-45F4-8153-73C5C4C6FCC7

Q37200831-464810E3-C37D-49B6-A0BB-44EF7BD01884

Q37200831-5AED9E0C-B70B-4532-A3C1-7CE763475B9E

Q37200831-5C79E112-D19E-4E2F-A052-E5CD0600C0F2

Q37200831-856E230F-1EDC-4D68-A1FB-5CC329B80E2E

Q37200831-956B7F82-CC84-4FC4-9248-E39EF500D5BE

Q37200831-A6573F75-FCB3-42AE-A291-900D3DD0C5CD

Q37200831-C0310B4C-05AE-4BDC-8202-C9660E4A6E59

Q37200831-C1AF2E80-E9F8-4485-B9D9-41294FB29450

Q37200831-D6FDEA5B-0EA7-4D47-9491-11041689BA5D

P2860

Q37200831-05C7FF8E-1967-4C42-99B6-C31850A69D4E

Q37200831-09F734F6-9B31-4DB1-AD1D-FB830F8B25CD

Q37200831-0B74CA01-A3BA-475D-957F-42EF366443E1

Q37200831-0F624743-2FE1-4E41-81CC-64C368E483AF

Q37200831-0FFB177D-E263-41DA-85B2-FE8BC2E7F1B7

Q37200831-11DA416C-2B93-4F98-B8BD-38B3EBF2CEA9

Q37200831-1349F4C4-D559-422D-9DD5-B1ABD48F869A

Q37200831-1415F5E5-3548-4AA2-AFFC-5C1921A85288

Q37200831-1747D567-E27A-4265-857D-7F5DC53788E2

Q37200831-208FF5AE-4D53-4817-8E7C-32C2242D2558

P304

Q37200831-29217207-A7FE-4388-99F2-823C3AAF46F2

P31

Q37200831-114993E4-AED5-4AE3-8B53-FC01CCE8F47D

P356

Q37200831-FFDC4770-CEF4-416F-9A94-7F042B26CB14

P407

Q37200831-E38A79A2-B56C-47ED-A5AD-4ED476AF11F2

P433

Q37200831-DF20F274-4684-4274-A524-21EFF0E6C737

P478

Q37200831-76B03872-6490-42DF-BDAD-A94F25707A16

P50

Q37200831-36052E9C-D627-47A8-B1C2-DB5A08606EEB

Q37200831-4CA4815C-CF6B-492D-8577-66750C3FB033

Q37200831-FA9139D1-C616-400F-8F64-A89CE650F846

P577

Q37200831-05061CEA-4B17-4A52-A467-C82CC441EA4E

P5875

Q37200831-36E70D7F-E04D-4EEE-81D9-4DAA5195E93D

P698

Q37200831-04BBBF54-5DAC-4F40-8DE4-5144D8BFB488

P932

Q37200831-9ADBC28E-8AE4-498A-AE79-FE15AACE072F

P356

P1433

Journal of Clinical Investigation

P1476

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

@en

P2093

Aleix Prat

http://www.w3.org/2001/XMLSchema#string

Andrew J Williams

http://www.w3.org/2001/XMLSchema#string

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Christian Young

http://www.w3.org/2001/XMLSchema#string

Donna J Hicks

http://www.w3.org/2001/XMLSchema#string

H Shelton Earp

http://www.w3.org/2001/XMLSchema#string

Jamie C Stanford

http://www.w3.org/2001/XMLSchema#string

Katherine Hutchinson

http://www.w3.org/2001/XMLSchema#string

Maria G Kuba

http://www.w3.org/2001/XMLSchema#string

Meghan M Morrison

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Gene expression profiling predicts clinical outcome of breast cancer

A gene-expression signature as a predictor of survival in breast cancer

Repeated observation of breast tumor subtypes in independent gene expression data sets

The erbB3 gene product is a receptor for heregulin

P304

4329-4343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI66764

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Charles M. Perou

Suleiman Massarweh

Justin M. Balko

P577

2013-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256375762

http://www.w3.org/2001/XMLSchema#string

P698

23999432

http://www.w3.org/2001/XMLSchema#string

P932

3784526

http://www.w3.org/2001/XMLSchema#string